< Back to latest news & events

News

Why the EPO’s top-up search for earlier national rights matters for the UP and UPC

January 2023

Before unitary effect can be registered by the EPO, an applicant must first obtain a European patent via the EPO as it does in the current way. In order to be eligible for registration as a Unitary Patent (“UP”), the European patent must have been granted with the same set of claims in respect of all the 25 participating Member States. This condition must be met irrespective of whether all these states will in fact be covered by the UP. This means that (i) withdrawing the designation of any of the 25 participating Member States rules out obtaining a UP and (ii) having a different set of claims for any of the participating Member States, would also prevent the EPO from registering a UP.

Earlier national rights (i.e. patent documents from the EPC contracting states that would potentially present a “novelty only” patentability problem) are not included in the state of the art for the purposes of the EPO’s examination for patentability (Article 54(3) EPC). This refers to national applications of which the filing dates are prior to the filing or priority date of the European application and which were published as national applications or patents on or after that date. However, under Article 139(2) EPC, after the European patent has been granted, earlier national rights can be invoked as a ground for revocation in national proceedings.

From 1 September 2022, the EPO has been carrying out systematic top-up searches to find such earlier national rights – this is usually reported as part of the EPO’s R71(3) communication (notice of intention to grant). The EPO already carries out a top-up search for European rights at the end of examination.

When it opens, the UPC may revoke a UP, either entirely or partly (Article 65 UPCA), only on the grounds referred to in Articles 138(1) and 139(2) of the EPC. As such, an earlier national right could become prior art against a UP before the UPC.

To avoid these earlier national rights, applicants can file separate sets of claims for countries in which earlier national rights are found (Rule 138 EPC). However, doing so would rule out a UP.

Applicants may therefore need to consider the finding of a national prior right carefully, as it will play into the decision on their validation strategy and whether a UP is the right approach.


This article was prepared by HGF Partners & Patent Attorneys Andy Camenisch and Dr Jennifer Uno

Latest updates

Event - 10th September 2025

Seminar on Incorporating Trade Secrets into your IP Strategy

HGF is hosting a Seminar on Incorporating Trade Secrets into your IP Strategy which will be followed by networking, apero, and snacks. The Seminar will be held on Wednesday, 10th …

Event details

EU Customs Recordals

Read article

HGF Partners Recognised in IAM Strategy 300 2025

The latest edition of IAM Strategy 300: The World’s Leading IP Strategists has now been published, and HGF is proud to announce that three of our partners have been listed …

Read article
Event - 25th September 2025

HGF Futures Life Sciences – Join our open day in London

An opportunity to discover your path to becoming a Life Science Patent Attorney! Are you a recent or soon-to-be graduate with a degree in Life Sciences? Are you passionate about …

Event details

Celebrating exam success at HGF

We would like to congratulate our colleagues on their recent exam success. Their dedication, perseverance, and commitment to professional development have led to success, and we are pleased to celebrate …

Read article
Event - 5th November 2025

IAM Navigating the UPC conference

HGF are gold sponsors of the IAM Live Navigating the UPC conference. The IAM Live Navigating the UPC will take place at the Marriott Opera Ambassador Hotel, Paris on 5th …

Event details

Post Sale Confusion – dupes and lookalikes beware?

Last month, the UK Supreme Court issued its highly-anticipated decision in Iconix Luxembourg Holdings SARL v Dream Pairs Europe Inc and another [2025] UKSC 25. Helpful background to the dispute …

Read article

A leading case - beware sequence errors in patent claims

Samsung Bioepis UK Ltd v Alexion Pharmaceuticals Inc [2025] EWHC 1240 (Pat) – Mr Justice Meade – 20 May 2025 The UK Patents Court has held that Samsung Bioepis’ and Amgen’s …

Read article